MAPT and Alzheimer disease: In this review, we aim to explore the (i) clinical evidence on the role of amyloid and tau pathology in MBI based on studies using AD biomarkers, (ii) the potential neurobiological mechanisms of MBI, with an emphasis on amyloid and tau pathology, and(iii) potential therapeutic implications.